Celerion Becomes Cardiac Safety Research Consortium Member
Celerion announced its membership into the Cardiac Safety Research Consortium
Celerion announced its membership into the Cardiac Safety Research Consortium (CSRC) to engage with other thought leaders on key issues that impact cardiovascular safety. This will include discussions regarding alternative approaches to ICH E14 to assess arrhythmia liability in early drug development.
As a provider of cardiovascular safety services in early clinical research, Celerion's activity highlights the company's leadership role and contributions in cardiovascular safety evaluation, and allows it to collaborate in critical discussions to ensure we deliver on our clients’ and public health needs.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
